混合闭环系统在 1 型糖尿病合并胃轻瘫成人患者中的疗效。
Efficacy of Hybrid Closed-Loop System in Adults with Type 1 Diabetes and Gastroparesis.
机构信息
Sunrise Health Consortium, Southern Hills Hospital Family Medicine GME, Las Vegas, Nevada.
Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
出版信息
Diabetes Technol Ther. 2019 Dec;21(12):736-739. doi: 10.1089/dia.2019.0254. Epub 2019 Aug 16.
We evaluated the efficacy of 670 G HCL on changes in HbA1c and continuous glucose monitor (CGM)-based glucose metrics at 3 and 6 months between five adults with T1D with gastroparesis and nine age-, sex-, and diabetes duration-matched T1D without gastroparesis. At baseline, there were no differences in age, gender, diabetes duration, and total daily insulin requirement between two groups. Median duration of gastroparesis diagnosis was 4.3 years (interquartile range [IQR]: 3.7, 5.9 years). Reduction in HbA1c [difference in HbA1c from baseline to 6 months, median (IQR): 0.3% (0.3%, 0.3%) vs. 0.5% (0.3%, 0.9%); = 0.20] and CGM time spent in normoglycemia at 6 months [median (IQR): 73% (68%, 80%) vs. 67% (64%, 74%); = 0.24] were not different between the groups. HCL has similar efficacy in glucose control in adults with T1D with gastroparesis and appears to be safe in this population.
我们评估了 670G HCL 在 5 名伴有胃轻瘫的 T1D 成人和 9 名年龄、性别和糖尿病病程匹配的无胃轻瘫 T1D 成人中，在 3 个月和 6 个月时对 HbA1c 和基于连续血糖监测（CGM）的血糖指标变化的疗效。在基线时，两组间在年龄、性别、糖尿病病程和总日胰岛素需求方面无差异。胃轻瘫诊断的中位持续时间为 4.3 年（四分位距[IQR]：3.7，5.9 年）。HbA1c 的降低[从基线到 6 个月的 HbA1c 差异，中位数（IQR）：0.3%（0.3%，0.3%）与 0.5%（0.3%，0.9%）； = 0.20]和 6 个月时 CGM 的正常血糖时间[中位数（IQR）：73%（68%，80%）与 67%（64%，74%）； = 0.24]在两组间无差异。HCL 在控制伴有胃轻瘫的 T1D 成人的血糖方面具有相似的疗效，并且在该人群中似乎是安全的。
Zotero 插件